Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rifabutin - capsules - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - nevirapine - tablets - nevirapine 200 mg - nevirapine - nevirapine - for use in combination with other antiretroviral agents for the treatment of hiv-1 infection.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nevirapine - hiv infections - antivirals for systemic use - tablets and oral suspensionviramune is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1-infected adults, adolescents, and children of any age.most of the experience with viramune is in combination with nucleoside reverse-transcriptase inhibitors (nrtis). the choice of a subsequent therapy after viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsviramune is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1-infected adolescents and children three years and above and able to swallow tablets.prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.most of the experience with viramune is in combination with nucleoside reverse-transcriptase inhibitors (nrtis). the choice of a subsequent therapy after viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsviramune is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1-infected adults, adolescents and children three years and above and able to swallow tablets.prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.most of the experience with viramune is in combination with nucleoside reverse-transcriptase inhibitors (nrtis). the choice of a subsequent therapy after viramune should be based on clinical experience and resistance testing.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infections - antivirals for systemic use - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).

European Union - English - EMA (European Medicines Agency)

merck sharp dohme limited - lamivudine, raltegravir potassium - hiv infections - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis is indicated in combination with other anti‑retroviral medicinal products for the treatment of human immunodeficiency virus (hiv‑1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the insti (integrase strand transfer inhibitor) and nrti (nucleoside reverse transcriptase inhibitor) classes (see sections 4.2, 4.4 and 5.1).

United States - English - NLM (National Library of Medicine)

gilead sciences, inc. - cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - cobicistat 150 mg - adult patients: tybost is a cyp3a inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of hiv-1 infection in adults [see dosage and administration (2.1)]. pediatric patients: tybost is a cyp3a inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of hiv-1 infection in pediatric patients [see dosage and administration (2.2)]: - weighing at least 35 kg coadministered with atazanavir or - weighing at least 40 kg coadministered with darunavir. - tybost is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. the use of tybost is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir [see warnings and precautions (5.4)]. - complex or u

European Union - English - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib disodium - thrombocytopenia - other systemic hemostatics - tavlesse is indicated for the treatment of chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

gilead sciences limited (cork), ireland - emtricitabine,elvitegravir,cobicistat,tenofovir alafenamide - film-coated tablet - 200,150,150,10 mg,

Canada - English - Health Canada

merck canada inc - elbasvir; grazoprevir - tablet - 50mg; 100mg - elbasvir 50mg; grazoprevir 100mg - hcv replication complex inhibitors

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

mylan laboratories limited, india - dolutegravir sodium - tablets - 50/200/25 mg